Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:6888 |
Name | ureter transitional cell carcinoma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer ureter cancer ureter carcinoma ureter transitional cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00942331 | Phase III | Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | Completed | USA | 1 |
NCT01108055 | Phase II | Paclitaxel + Pazopanib | Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer | Completed | USA | 0 |
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT01215136 | Phase II | Everolimus Paclitaxel | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | Terminated | USA | 0 |
NCT01326871 | Phase Ib/II | ALT-801 | A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer | Completed | USA | 0 |
NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
NCT01780545 | Phase II | Apatorsen Docetaxel | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | Completed | USA | 0 |
NCT02014337 | Phase I | Eribulin + Mifepristone | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Completed | USA | 0 |
NCT02091999 | Phase I | Enfortumab vedotin-ejfv | A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | Completed | USA | CAN | 0 |
NCT02108652 | Phase II | Atezolizumab | A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | 0 |
NCT02122172 | Phase II | Afatinib | Afatinib in Advanced Refractory Urothelial Cancer | Terminated | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02236195 | Phase II | Mocetinostat | Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes | Completed | USA | 0 |
NCT02240238 | Phase Ib/II | Gemcitabine + NC-6004 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | Completed | USA | ROU | POL | ITA | BGR | 0 |
NCT02256436 | Phase III | Pembrolizumab | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | Completed | 0 | |
NCT02300610 | Phase I | Cisplatin + Gemcitabine Enzalutamide | Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | Completed | USA | 0 |
NCT02302807 | Phase III | Paclitaxel Vinorelbine Atezolizumab Docetaxel | A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | Completed | USA | TUR | SWE | SVN | ROU | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 6 |
NCT02334527 | Phase II | Palbociclib | Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy | Terminated | USA | 0 |
NCT02335424 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) | Completed | 0 | |
NCT02365766 | Phase Ib/II | Cisplatin Pembrolizumab Gemcitabine | Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer | Active, not recruiting | USA | 0 |
NCT02365818 | Phase II | CG0070 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure | Completed | USA | 0 |
NCT02387996 | Phase II | Nivolumab | A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer | Completed | USA | SWE | POL | ITA | FIN | ESP | DEU | CZE | BEL | AUS | 1 |
NCT02401542 | Phase Ib/II | Docetaxel + Vofatamab Vofatamab Docetaxel | Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21) | Terminated | USA | TUR | SWE | ITA | GBR | ESP | CZE | 2 |
NCT02412670 | Phase II | Carboplatin + Gemcitabine Aldoxorubicin + Cisplatin + Methotrexate + Vincristine Sulfate | Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer | Completed | USA | 0 |
NCT02426125 | Phase III | Ramucirumab Docetaxel | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer | Completed | USA | TUR | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 6 |
NCT02437370 | Phase I | Pembrolizumab Gemcitabine Docetaxel | Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer | Completed | USA | 0 |
NCT02443324 | Phase I | Pembrolizumab + Ramucirumab | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium | Completed | USA | GBR | FRA | ESP | DEU | 1 |
NCT02459119 | Phase II | Regorafenib | Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) | Completed | USA | 0 |
NCT02479178 | Phase II | BIND-014 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) | Terminated | USA | 1 |
NCT02496208 | Phase I | Ipilimumab Cabozantinib + Nivolumab | Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors | Active, not recruiting | USA | 0 |
NCT02500121 | Phase II | Pembrolizumab | Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer | Completed | USA | 0 |
NCT02516241 | Phase III | Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab | Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS | 7 |
NCT02553642 | Phase II | Nivolumab Ipilimumab | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | Completed | USA | 0 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02567409 | Phase II | Cisplatin + Gemcitabine Berzosertib + Cisplatin + Gemcitabine | Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer | Active, not recruiting | USA | 0 |
NCT02581982 | Phase II | Pembrolizumab Paclitaxel | Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer | Completed | USA | 0 |
NCT02589717 | FDA approved | Atezolizumab | An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy | Approved for marketing | USA | 0 |
NCT02612194 | Phase II | Crizotinib | LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer | Terminated | USA | 0 |
NCT02619253 | Phase Ib/II | Pembrolizumab + Vorinostat | Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma | Completed | USA | 0 |
NCT02632409 | Phase III | Nivolumab | A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma | Active, not recruiting | USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Completed | USA | NLD | FRA | CAN | 0 |
NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
NCT02807636 | Phase III | Atezolizumab + Carboplatin + Gemcitabine Carboplatin + Gemcitabine | The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy | Completed | USA | TUR | SVN | ROU | POL | NLD | ITA | ISR | GRC | GBR | FIN | EST | ESP | CZE | CAN | BRA | BEL | AUS | 17 |
NCT02812420 | Phase I | Durvalumab + Tremelimumab | Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy | Active, not recruiting | USA | 0 |
NCT02853305 | Phase III | Pembrolizumab Carboplatin + Cisplatin + Gemcitabine | Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) | Completed | 0 | |
NCT02872714 | Phase II | Pemigatinib | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | Completed | USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | BEL | 1 |
NCT02897765 | Phase I | Nivolumab NEO-PV-01 + Poly ICLC | A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | Completed | USA | 0 |
NCT02925533 | Phase I | Pembrolizumab + Vofatamab | Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract | Terminated | USA | 0 |
NCT02989064 | Phase I | MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers | Completed | USA | ESP | CAN | 0 | |
NCT02989584 | Phase Ib/II | Atezolizumab + Cisplatin + Gemcitabine | A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03093922 | Phase II | Atezolizumab + Cisplatin + Gemcitabine | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03132922 | Phase I | afamitresgene autoleucel | MAGE-A4c1032T for Multi-Tumor | Active, not recruiting | USA | CAN | 0 |
NCT03170960 | Phase Ib/II | Atezolizumab + Cabozantinib | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03237780 | Phase II | Atezolizumab Atezolizumab + Eribulin | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | Active, not recruiting | USA | 0 |
NCT03272217 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | Terminated | USA | 0 |
NCT03317496 | Phase II | Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | Terminated | USA | ITA | HUN | GBR | ESP | CZE | CAN | AUS | 0 |
NCT03345134 | Phase II | BCG solution + Pembrolizumab | Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy | Not yet recruiting | USA | 0 |
NCT03359239 | Phase I | Atezolizumab + PGV 001 | Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer | Completed | USA | 0 |
NCT03361865 | Phase III | Epacadostat + Pembrolizumab Pembrolizumab | Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) | Completed | USA | POL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 5 |
NCT03374488 | Phase III | Epacadostat + Pembrolizumab Pembrolizumab | Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma | Completed | USA | TUR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 4 |
NCT03397394 | Phase II | Rucaparib | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS) | Terminated | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03410693 | Phase II | Docetaxel Vinflunine Paclitaxel Rogaratinib | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1) | Completed | USA | SWE | SVK | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 8 |
NCT03425201 | Phase Ib/II | Cabozantinib + Niraparib | Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (NICARAGUA) | Completed | ESP | 0 |
NCT03451331 | Phase II | Carboplatin + Gemcitabine + Nivolumab Gemcitabine + Nivolumab + Oxaliplatin | Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer | Completed | USA | 0 |
NCT03459846 | Phase II | Durvalumab + Olaparib Durvalumab | A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU) | Active, not recruiting | USA | ESP | CAN | 4 |
NCT03472274 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Vinblastine Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Paclitaxel Durvalumab + Tremelimumab | Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (DUTRENEO) | Completed | ESP | 0 |
NCT03473756 | Phase Ib/II | Atezolizumab Atezolizumab + Rogaratinib | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) | Completed | USA | ITA | FRA | ESP | DEU | AUT | 2 |
NCT03502681 | Phase I | Avelumab + Eribulin | A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients | Terminated | USA | 0 |
NCT03502785 | Phase Ib/II | Atezolizumab + INO-5401 + INO-9012 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | Active, not recruiting | USA | 0 |
NCT03513952 | Phase II | Atezolizumab + CYT107 Atezolizumab | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | Completed | USA | 0 |
NCT03517956 | Phase I | Copanlisib + Rogaratinib | Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO) | Completed | USA | ESP | DEU | BEL | 2 |
NCT03520231 | Phase II | Carboplatin + Cisplatin + Denosumab + Gemcitabine Carboplatin + Cisplatin + Gemcitabine | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | Completed | CAN | 0 |
NCT03557918 | Phase II | Tremelimumab | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | Completed | USA | 0 |
NCT03575013 | Phase I | Avelumab + Docetaxel | A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer | Active, not recruiting | USA | 0 |
NCT03628716 | Phase II | Atezolizumab + CV301 | CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | Completed | USA | 0 |
NCT03666988 | Phase I | GSK3368715 | First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) | Terminated | USA | ESP | CAN | AUS | 0 |
NCT03674424 | Phase II | Avelumab + Gemcitabine + Paclitaxel Avelumab + Cisplatin + Doxorubicin + Methotrexate + Vinblastine Avelumab Avelumab + Cisplatin + Gemcitabine | Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA) | Active, not recruiting | FRA | BEL | 0 |
NCT03682068 | Phase III | Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine | Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE) | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | ESP | CZE | CAN | BRA | BGR | AUS | ARG | 9 |
NCT03737123 | Phase II | Atezolizumab + Carboplatin + Gemcitabine | Trial of Atezolizumab Plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | Terminated | USA | 0 |
NCT03775265 | Phase III | Atezolizumab + Cisplatin + Mitomycin C Fluorouracil + Mitomycin C Atezolizumab + Gemcitabine + Mitomycin C Gemcitabine + Mitomycin C Atezolizumab + Fluorouracil + Mitomycin C Cisplatin + Mitomycin C | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03821935 | Phase I | ABBV-151 ABBV-151 + Budigalimab | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | ISR | FRA | ESP | CAN | BEL | AUS | 4 |
NCT03824691 | Phase II | Cabozantinib + Durvalumab | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" (ARCADIA) | Unknown status | ITA | 0 |
NCT03869190 | Phase Ib/II | Atezolizumab + Tocilizumab Atezolizumab + Niraparib Atezolizumab + Hu5F9-G4 Atezolizumab + Enfortumab vedotin-ejfv Atezolizumab + Linagliptin Atezolizumab + Isatuximab Atezolizumab | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS mUC) | Active, not recruiting | USA | GRC | GBR | FRA | ESP | 2 |
NCT03898180 | Phase III | Lenvatinib + Pembrolizumab Pembrolizumab | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | Completed | USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS | ARG | 5 |
NCT03915405 | Phase I | Avelumab + KHK2455 | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer | Terminated | USA | ESP | 0 |
NCT03935347 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + LN-145 + Pembrolizumab | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | Withdrawn | USA | 0 |
NCT03980041 | Phase II | Nivolumab Eganelisib + Nivolumab | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | Completed | USA | POL | ITA | FRA | ESP | CZE | 1 |
NCT04004442 | Phase II | AVB-S6-500 + Avelumab | Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (COAXIN) | Active, not recruiting | USA | 0 |
NCT04064190 | Phase II | Durvalumab + Vactosertib | Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | Not yet recruiting | USA | 0 |
NCT04066595 | Phase II | Cabozantinib | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. (CabUC) | Terminated | DEU | 0 |
NCT04143711 | Phase Ib/II | DF1001 DF1001 + Pembrolizumab | Study of DF1001 in Patients With Advanced Solid Tumors | Recruiting | USA | NLD | FRA | DNK | BEL | 0 |
NCT04228042 | Phase Ib/II | Infigratinib | Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer | Completed | USA | 0 |
NCT04294277 | Phase II | Pemigatinib | Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery (PEGASUS) | Terminated | ITA | 0 |
NCT04349280 | Phase I | Bintrafusp alfa | A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer | Terminated | USA | NLD | FRA | ESP | CAN | 0 |
NCT04501094 | Phase II | Bintrafusp alfa | A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma | Terminated | USA | 0 |
NCT04602078 | Phase II | Atezolizumab + Cisplatin + Gemcitabine | Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma (AUREA) | Completed | ESP | 0 |
NCT04624399 | Phase II | Atezolizumab | Phase 2 Study of Neoadjuvant Immune Checkpoint Inhibitors in Urothelial Cancer (ABACUS-2) | Recruiting | GBR | 0 |
NCT04628767 | Phase III | Durvalumab + Gemcitabine Cisplatin + Doxorubicin + Methotrexate + Pegfilgrastim + Vinblastine Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Pegfilgrastim + Vinblastine | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Recruiting | USA | 0 |
NCT04637594 | Phase III | Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | Active, not recruiting | USA | 0 |
NCT04678362 | Phase II | Avelumab + Talazoparib | TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma (TALASUR) | Recruiting | FRA | 0 |
NCT04701918 | Phase II | Pembrolizumab | Pembrolizumab And Cryoablation In Urothelial Carcinoma | Recruiting | USA | 0 |
NCT04724018 | Phase I | Enfortumab vedotin-ejfv + Sacituzumab govitecan-hziy | Sacituzumab Govitecan Plus EV in Metastatic UC | Active, not recruiting | USA | 0 |
NCT04848519 | Phase II | Pembrolizumab + Propranolol | Propranolol Hydrochloride and Pembrolizumab for the Treatment of Recurrent or Metastatic Urothelial Cancer | Recruiting | USA | 0 |
NCT04871529 | Phase II | Avelumab + Carboplatin + Gemcitabine | Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) | Suspended | USA | 0 |
NCT04879329 | Phase II | Disitamab vedotin Disitamab vedotin + Pembrolizumab | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Recruiting | USA | ITA | ISR | GBR | ESP | CAN | BEL | AUS | ARG | 2 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |
NCT04940299 | Phase II | Ipilimumab + Nivolumab + Tocilizumab | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | Active, not recruiting | USA | 0 |
NCT04953104 | Phase II | Nivolumab | Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression | Recruiting | USA | 0 |
NCT04963153 | Phase I | Enfortumab vedotin-ejfv + Erdafitinib | Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | Recruiting | USA | CAN | 0 |
NCT05077709 | Phase II | IO102-IO103 + Pembrolizumab | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | Active, not recruiting | USA | GBR | ESP | 0 |
NCT05092958 | Phase III | Avelumab + Cabozantinib Avelumab | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study | Active, not recruiting | USA | CAN | 0 |
NCT05176483 | Phase I | Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) | Recruiting | USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
NCT05219435 | Phase II | Ipilimumab + Nivolumab | Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (VEXILLUM) | Recruiting | ESP | 0 |
NCT05239624 | Phase II | Enfortumab vedotin-ejfv + Pembrolizumab | Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | Recruiting | USA | 0 |
NCT05562830 | Phase Ib/II | VLS-101 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | Active, not recruiting | USA | ISR | ESP | DNK | AUS | 2 |
NCT05656235 | Phase II | Enfortumab vedotin-ejfv + Pembrolizumab | Renal Retention in High Grade Upper Tract Urothelial Cancer | Not yet recruiting | USA | 0 |
NCT05868265 | Phase II | Enfortumab vedotin-ejfv | A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract | Recruiting | USA | 0 |
NCT05894447 | Phase I | Naptumomab estafenatox + Pembrolizumab Obinutuzumab | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers | Withdrawn | USA | 0 |
NCT05911295 | Phase III | Disitamab vedotin + Pembrolizumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Recruiting | USA | ITA | ISR | FRA | ESP | CAN | BRA | AUS | ARG | 5 |
NCT06225596 | Phase II | Avelumab + Carboplatin + Gemcitabine Avelumab + Cisplatin + Gemcitabine BT8009 BT8009 + Pembrolizumab | Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | Recruiting | USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | ARG | 5 |
NCT06356155 | Phase II | Enfortumab vedotin-ejfv + Pembrolizumab | Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer (NEPTUNE) | Not yet recruiting | USA | 0 |
NCT06630247 | Phase I | XL495 | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06660654 | Phase II | Raludotatug deruxtecan | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Not yet recruiting | USA | 0 |